JP2016503391A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503391A5 JP2016503391A5 JP2015538050A JP2015538050A JP2016503391A5 JP 2016503391 A5 JP2016503391 A5 JP 2016503391A5 JP 2015538050 A JP2015538050 A JP 2015538050A JP 2015538050 A JP2015538050 A JP 2015538050A JP 2016503391 A5 JP2016503391 A5 JP 2016503391A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- fluoro
- item
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MZHRFHRSYBBMON-UHFFFAOYSA-N CC(C)(C)OCCONC(c(c(Nc(ccc(Br)c1)c1F)c1F)cc2c1nc[n]2C)=O Chemical compound CC(C)(C)OCCONC(c(c(Nc(ccc(Br)c1)c1F)c1F)cc2c1nc[n]2C)=O MZHRFHRSYBBMON-UHFFFAOYSA-N 0.000 description 2
- 0 *CNOCCOc1ccccc1 Chemical compound *CNOCCOc1ccccc1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261716169P | 2012-10-19 | 2012-10-19 | |
| US61/716,169 | 2012-10-19 | ||
| PCT/US2013/065633 WO2014063024A1 (en) | 2012-10-19 | 2013-10-18 | Preparation of and formulation comprising a mek inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018109486A Division JP6737838B2 (ja) | 2012-10-19 | 2018-06-07 | Ｍｅｋ阻害剤の調製およびｍｅｋ阻害剤を含む製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016503391A JP2016503391A (ja) | 2016-02-04 |
| JP2016503391A5 true JP2016503391A5 (https=) | 2016-12-01 |
| JP6385939B2 JP6385939B2 (ja) | 2018-09-05 |
Family
ID=50488781
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015538050A Active JP6385939B2 (ja) | 2012-10-19 | 2013-10-18 | Ｍｅｋ阻害剤の調製およびｍｅｋ阻害剤を含む製剤 |
| JP2018109486A Active JP6737838B2 (ja) | 2012-10-19 | 2018-06-07 | Ｍｅｋ阻害剤の調製およびｍｅｋ阻害剤を含む製剤 |
| JP2019149828A Pending JP2019194272A (ja) | 2012-10-19 | 2019-08-19 | Ｍｅｋ阻害剤の調製およびｍｅｋ阻害剤を含む製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018109486A Active JP6737838B2 (ja) | 2012-10-19 | 2018-06-07 | Ｍｅｋ阻害剤の調製およびｍｅｋ阻害剤を含む製剤 |
| JP2019149828A Pending JP2019194272A (ja) | 2012-10-19 | 2019-08-19 | Ｍｅｋ阻害剤の調製およびｍｅｋ阻害剤を含む製剤 |
Country Status (23)
| Country | Link |
|---|---|
| US (7) | US9238627B2 (https=) |
| EP (3) | EP4306171A3 (https=) |
| JP (3) | JP6385939B2 (https=) |
| CN (3) | CN109336824B (https=) |
| AR (1) | AR099630A1 (https=) |
| BR (1) | BR112015008623B1 (https=) |
| CA (2) | CA3079071C (https=) |
| CY (1) | CY1122670T1 (https=) |
| DK (2) | DK2909182T3 (https=) |
| ES (2) | ES2971077T3 (https=) |
| FI (1) | FI3702351T3 (https=) |
| HR (1) | HRP20240033T1 (https=) |
| HU (2) | HUE065433T2 (https=) |
| JO (1) | JOP20130304B1 (https=) |
| LT (1) | LT3702351T (https=) |
| PL (2) | PL3702351T3 (https=) |
| PT (2) | PT3702351T (https=) |
| RS (1) | RS65117B1 (https=) |
| RU (2) | RU2018127873A (https=) |
| SI (2) | SI3702351T1 (https=) |
| SM (1) | SMT202400044T1 (https=) |
| TW (1) | TWI650316B (https=) |
| WO (1) | WO2014063024A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR099630A1 (es) | 2012-10-19 | 2016-08-10 | Novartis Ag | Preparación de un inhibidor de mek y formulación que lo comprende |
| CN105566225A (zh) * | 2015-02-16 | 2016-05-11 | 苏州晶云药物科技有限公司 | 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法 |
| MX387795B (es) * | 2016-06-03 | 2025-03-19 | Array Biopharma Inc | Combinaciones farmaceuticas. |
| CN111646946A (zh) * | 2017-11-14 | 2020-09-11 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的苯并咪唑化合物及包含该化合物的组合物 |
| TW201938165A (zh) | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | 治療癌症的方法及組合療法 |
| WO2019139970A1 (en) * | 2018-01-09 | 2019-07-18 | Duke University | Topical administration of mek inhibiting agents for the treatment of skin disorders |
| WO2020212832A1 (en) * | 2019-04-16 | 2020-10-22 | Alembic Pharmaceuticals Limited | Process of preparation of benzimidazole compounds |
| WO2021116901A1 (en) * | 2019-12-09 | 2021-06-17 | Biocon Limited | Forms of binimetinib and process for preparation thereof |
| AU2021358394A1 (en) | 2020-10-05 | 2023-04-13 | Pierre Fabre Medicament | Combination of encorafenib and binimetinib as adjuvant treatment for resected stage II melanoma |
| CN112679438A (zh) * | 2020-12-31 | 2021-04-20 | 武汉九州钰民医药科技有限公司 | 制备司美替尼的方法 |
| EP4346826A4 (en) | 2021-05-27 | 2025-04-30 | Mirati Therapeutics, Inc. | COMBINATION THERAPIES |
| WO2023084489A1 (en) | 2021-11-15 | 2023-05-19 | Pfizer Inc. | Methods of treating coronavirus disease 2019 |
| EP4460303A4 (en) * | 2022-01-06 | 2025-07-23 | Msn Laboratories Private Ltd R&D Center | IMPROVED PROCESS FOR THE PREPARATION OF 5-[(4-BROMO-2-FLUOROPHENYL)AMINO]-4-FLUORO-N-(2HYDROXYETHOXY)-1-METHYL-1H-BENZIMIDAZOLE-6-CARBOXAMIDE |
| WO2024003942A1 (en) * | 2022-07-01 | 2024-01-04 | Natco Pharma Limited | An improved process for the preparation of selumetinib sulfate |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| FR3159741A1 (fr) | 2024-03-04 | 2025-09-05 | Pierre Fabre Medicament | Formulation topique comprenant du binimetinib |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2355470C (en) * | 1999-01-13 | 2008-09-30 | Warner-Lambert Company | Benzoheterocycles and their use as mek inhibitors |
| CA2377092A1 (en) * | 1999-07-16 | 2001-01-25 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
| US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| SG2013013339A (en) * | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| CA2532067C (en) * | 2003-07-24 | 2010-12-21 | Stephen Douglas Barrett | N-methyle-substituted benzamidazoles |
| AU2005283422C1 (en) | 2004-09-17 | 2017-02-02 | Eisai R & D Management Co., Ltd. | Medicinal composition |
| US8039637B2 (en) | 2005-06-23 | 2011-10-18 | Array Biopharma Inc. | Process for preparing benzimidazole compounds |
| EP1904061B1 (en) | 2005-06-23 | 2018-12-26 | Array Biopharma, Inc. | SNAr PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS |
| WO2009018233A1 (en) * | 2007-07-30 | 2009-02-05 | Ardea Biosciences, Inc. | Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same |
| TWI405756B (zh) * | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | 新穎硫酸氫鹽 |
| EP1966155A1 (en) * | 2005-12-21 | 2008-09-10 | AstraZeneca AB | Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer |
| WO2009064675A1 (en) | 2007-11-12 | 2009-05-22 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
| BRPI0925050A2 (pt) * | 2009-04-21 | 2015-08-04 | Novartis Ag | Compostos heterocíclicos como inibidores de mek |
| WO2012145503A1 (en) | 2011-04-21 | 2012-10-26 | Novartis Ag | Pharmaceutical combinations |
| JP2014528928A (ja) | 2011-09-01 | 2014-10-30 | ノバルティス アーゲー | ヌーナン症候群の治療のための有機化合物の使用 |
| AR099630A1 (es) | 2012-10-19 | 2016-08-10 | Novartis Ag | Preparación de un inhibidor de mek y formulación que lo comprende |
-
2013
- 2013-10-18 AR ARP130103796A patent/AR099630A1/es not_active Application Discontinuation
- 2013-10-18 PL PL19211405.6T patent/PL3702351T3/pl unknown
- 2013-10-18 DK DK13847106.5T patent/DK2909182T3/da active
- 2013-10-18 ES ES19211405T patent/ES2971077T3/es active Active
- 2013-10-18 HU HUE19211405A patent/HUE065433T2/hu unknown
- 2013-10-18 FI FIEP19211405.6T patent/FI3702351T3/fi active
- 2013-10-18 RS RS20240112A patent/RS65117B1/sr unknown
- 2013-10-18 BR BR112015008623-3A patent/BR112015008623B1/pt active IP Right Grant
- 2013-10-18 PT PT192114056T patent/PT3702351T/pt unknown
- 2013-10-18 PL PL13847106T patent/PL2909182T3/pl unknown
- 2013-10-18 SI SI201332074T patent/SI3702351T1/sl unknown
- 2013-10-18 SM SM20240044T patent/SMT202400044T1/it unknown
- 2013-10-18 RU RU2018127873A patent/RU2018127873A/ru not_active Application Discontinuation
- 2013-10-18 EP EP23211278.9A patent/EP4306171A3/en active Pending
- 2013-10-18 PT PT138471065T patent/PT2909182T/pt unknown
- 2013-10-18 CN CN201811124073.6A patent/CN109336824B/zh active Active
- 2013-10-18 CN CN201810684986.7A patent/CN109456272A/zh active Pending
- 2013-10-18 US US14/057,498 patent/US9238627B2/en active Active
- 2013-10-18 ES ES13847106T patent/ES2772498T3/es active Active
- 2013-10-18 CN CN201380063271.5A patent/CN104870427B/zh active Active
- 2013-10-18 WO PCT/US2013/065633 patent/WO2014063024A1/en not_active Ceased
- 2013-10-18 EP EP19211405.6A patent/EP3702351B1/en active Active
- 2013-10-18 JP JP2015538050A patent/JP6385939B2/ja active Active
- 2013-10-18 HU HUE13847106A patent/HUE047708T2/hu unknown
- 2013-10-18 LT LTEP19211405.6T patent/LT3702351T/lt unknown
- 2013-10-18 DK DK19211405.6T patent/DK3702351T3/da active
- 2013-10-18 SI SI201331672T patent/SI2909182T1/sl unknown
- 2013-10-18 TW TW102137813A patent/TWI650316B/zh active
- 2013-10-18 HR HRP20240033TT patent/HRP20240033T1/hr unknown
- 2013-10-18 CA CA3079071A patent/CA3079071C/en active Active
- 2013-10-18 CA CA2888474A patent/CA2888474C/en active Active
- 2013-10-18 RU RU2015118572A patent/RU2669391C2/ru active
- 2013-10-18 EP EP13847106.5A patent/EP2909182B1/en active Active
- 2013-10-20 JO JOP/2013/0304A patent/JOP20130304B1/ar active
-
2015
- 2015-12-18 US US14/974,655 patent/US9562016B2/en active Active
- 2015-12-18 US US14/974,588 patent/US9382212B1/en active Active
-
2016
- 2016-02-25 US US15/053,441 patent/US9598376B2/en active Active
-
2017
- 2017-02-28 US US15/445,393 patent/US9980944B2/en active Active
- 2017-12-14 US US15/842,715 patent/US10398683B2/en active Active
-
2018
- 2018-06-07 JP JP2018109486A patent/JP6737838B2/ja active Active
-
2019
- 2019-07-16 US US16/512,823 patent/US10729678B2/en active Active
- 2019-08-19 JP JP2019149828A patent/JP2019194272A/ja active Pending
-
2020
- 2020-02-18 CY CY20201100148T patent/CY1122670T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016503391A5 (https=) | ||
| RU2015118572A (ru) | Получение и составление композиции, содержащей ингибитор мек | |
| CN101891738B (zh) | 达沙替尼多晶型物及其制备方法和药用组合物 | |
| TWI749934B (zh) | 製備2-氟-4-甲基-5-(4-環丙基-1h-咪唑-1-基)苯甲酸之方法 | |
| JP6267213B2 (ja) | ５−（２，６−ジ−４−モルホリニル−４−ピリミジニル）−４−トリフルオロメチルピリジン−２−アミンを製造するための改良された方法 | |
| EP3672968B1 (en) | Solid state form of ribociclib succinate | |
| JP2018111713A (ja) | ヒドラジド含有核輸送調節因子およびその使用 | |
| JP2010503694A5 (https=) | ||
| CN104936961A (zh) | (1s,4s,5s)-4-溴-6-氧杂二环[3.2.1]辛-7-酮的制备方法 | |
| EP2707367B1 (en) | Methods for preparing naphthyridines | |
| AU2007267612A1 (en) | Preparation and utility of substituted carboxylic acid compounds | |
| CN101967140A (zh) | 氘代克里唑蒂尼及其衍生物、制备方法和应用 | |
| KR102660864B1 (ko) | 에라바사이클린의 결정질 형태 | |
| WO2016074532A1 (zh) | 艾立替尼的制备方法 | |
| CA2565629A1 (en) | Process for preparing atazanavir bisulfate and novel forms | |
| TW201831495A (zh) | 製備細胞毒性苯二氮平衍生物之方法 | |
| CN102875634A (zh) | 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型 | |
| CN102675395B (zh) | 醋酸乌利司他的多晶型及其制备方法 | |
| TW202421625A (zh) | 新穎sik抑制劑 | |
| KR20160068799A (ko) | 신규 화합물 | |
| CN105315260A (zh) | 一种托布司他一水合物晶型及其制备方法 | |
| CN102250084A (zh) | 达沙替尼多晶型物及其制备方法和药用组合物 | |
| TW201041855A (en) | New process for preparing | |
| JP2020073523A (ja) | 置換されたイミダゾピリジニル−アミノピリジン化合物の塩および多型 | |
| CN105985329B (zh) | 一种新的泊沙康唑化合物制备方法 |